Clinical Trials › NCT05925049
Active, Not Recruiting
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Sponsored by Biogen
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 400
Target enrollment
1
U.S. states
Jun 2023
Start date
Mar 2026
Expected completion
Interventions / Treatments
Natalizumab
Conditions studied
Multiple Sclerosis
Where this trial is running (1 site)
Massachusetts1 site
Cambridge
MS centers in Massachusetts
Compare treatment centers near a trial site by center type, providers and trials.
View Massachusetts centers